Daniel Ganger, MD
Hepatology · Chicago, ILNPI 1407821689
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Gilead at 58.7% of the total. Reporting peaked in 2019 at $22,537 and has fallen 99.4% since, to $131 in 2025.
Across 76 payments — averaging $757.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$34K
- AstraZeneca$15K
- Mallinckrodt Enterprises LLC$8K
- Mirum Pharmaceuticals, Inc.$100
- Cook Medical LLC$97
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$27
- plus $22 from 1 others
Across 24 payments — averaging $5560.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharma Europe Ltd.$70K
- Bausch Health US, LLC$25K
- Mallinckrodt Enterprises LLC$17K
- AbbVie$13K
- Merck$4K
- AstraZeneca$4K
What the payments were for
- Consulting fees$24,31042%
- Speaking & faculty fees$26,76546%
- Travel & lodging$4,7678%
- Food & beverage$1,7433%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 49 | $33,794 |
| AstraZeneca(2 entities) | 17 | $15,381 |
| Mallinckrodt Enterprises LLC | 6 | $8,181 |
| Mirum Pharmaceuticals, Inc. | 1 | $100 |
| Cook Medical LLC | 1 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $27 |
| Novo Nordisk | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$22,127
How this compares
$57,601 in reported general payments places this provider in the 80th percentile of 21 hepatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 48 | $196,792 |
| Everolimus | 49 | $179,011 |
| OcalivaObeticholic Acid | 13 | $125,452 |
| VemlidyTenofovir Alafenamide | 44 | $91,214 |
| Tacrolimus | 451 | $45,800 |
| Ursodiol | 207 | $26,275 |
| Tenofovir Disoproxil Fumarate | 49 | $18,987 |
| Mycophenolate Mofetil | 147 | $12,967 |
| Envarsus XrTacrolimus | 21 | $10,563 |
| Entecavir | 42 | $8,203 |
| Cyclosporine ModifiedCyclosporine, Modified | 20 | $3,566 |
| Mycophenolic AcidMycophenolate Sodium | 17 | $3,079 |
| Sirolimus | 13 | $2,109 |
| Lactulose | 24 | $1,349 |
| Pravastatin Sodium | 16 | $744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $27 | $196,79248 claims |
| GileadVemlidy | $33,794 | $91,21444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 hepatology providers in Illinois.
Other hepatology in Chicago
- Sean KoppeChicago$152K
- Veronica LoyChicago$78K
- Amanda CheungChicago$64K
- Christopher MooreChicago$57K
- Justin BoikeChicago$24K
- Andres DuarteChicago$11K
- Anna PatelChicago$6K
- Sarang ThakerChicago$6K
- Sheila EswaranChicago$1K
- Sonu DhillonChicago$995
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.